Hi,
moomoo ID:NaN
Log Out
English
Back
Log in to access Online Inquiry
Multi-dimentional Analyses
Company Valuation Capital Tracking Short Selling Data
Moomoo > Quotes > LLY Eli Lilly and Co > Key Indicators
LLY Eli Lilly and Co
371.790
-0.180-0.05%
Post Mkt Price
371.7900.0000.00%
YOY
Do not show
Hide blank lines
(Q3)2022/09/30(Q2)2022/06/30(Q1)2022/03/31(FY)2021/12/31
Financial Ratios
Efficiency Ratios TTM
Cash Conversion Cycle(D)
3.17% 193.6857 3.52% 193.2906 -5.07% 183.1025 -9.51% 195.3913
Receivable Turnover(T)
-9.92% 4.6303 -4.93% 4.7681 3.31% 4.9219 -4.15% 4.5136
Inventory Turnover(T)
-1.50% 1.8432 -6.16% 1.8082 9.34% 1.9874 21.58% 1.8593
Fixed Assets Turnover(T)
-0.62% 3.2075 1.83% 3.233 7.24% 3.3072 11.61% 3.2058
Total Asset Rate(T)
1.46% 0.6114 2.93% 0.6128 7.92% 0.6255 3.89% 0.5934
ROIC
-7.73% 24.783% -15.77% 24.691% -10.85% 26.200% -23.42% 24.394%
ROE
-28.69% 67.686% -34.09% 75.943% -38.15% 75.533% -49.16% 76.353%
ROA
-2.69% 12.615% -11.28% 11.998% -5.64% 13.075% -18.87% 11.697%
FCF to Sales
9.68% 18.258% -5.92% 17.026% -9.03% 19.862% 4.43% 19.025%
FCF to Net Income
14.37% 88.487% 9.15% 86.965% 4.03% 95.022% 33.73% 96.521%
Efficiency Ratios
ROE 5 Year Average
-- -- -- -- -- -- 17.24% 77.779%
ROA 5 Year Average
-- -- -- -- -- -- 8.93% 10.579%
Average 5 Years ROIC
-- -- -- -- -- -- 12.58% 22.282%
Profitability Ratios TTM
Gross Margin
1.02% 75.609% 2.31% 75.977% -1.95% 74.401% -4.48% 74.177%
Operating Margin
8.29% 29.173% 16.81% 29.732% 7.66% 28.780% -4.51% 26.654%
Net Margin
-4.10% 20.634% -13.81% 19.579% -12.56% 20.903% -21.91% 19.711%
EBITDA Margin
-6.50% 0.2897% -14.37% 0.2812% -13.87% 0.2968% -21.81% 0.284%
R & D Expense Ratio
-1.17% 24.580% -2.13% 24.390% -5.11% 23.750% 0.04% 24.810%
Sales Expense Ratio
-- 0.000% -- 0.000% -- 0.000% -- 0.000%
Administration Expense Rate
-- 0.000% -- 0.000% -- 0.000% -- 0.000%
Financial Health Ratios
Long-Term Debt to Equity Ratio
-- -- -24.81% 171.943% -30.84% 162.397% -41.87% 170.911%
Total Assets to Common Equity
-- -- -25.76% 550.793% -25.94% 502.843% -34.24% 543.545%
Debt to Asset Ratio
-- -- -23.22% 196.775% -24.68% 176.928% -36.07% 188.042%
Current Ratio
-- -- -4.38% 1.0957 -10.59% 1.2673 -12.38% 1.2259
Quick Ratio
-- -- -1.14% 0.6664 -6.50% 0.775 -5.94% 0.7996
GrowthRatios
Growth Ratios
Revenue CAGR(3Y)
-- -- -- -- -- -- 104.93% 4.867%
Revenue CAGR(5Y)
-- -- -- -- -- -- 40.76% 5.939%
Net Income CAGR(3Y)
-- -- -- -- -- -- -- 19.977%
Net Income CAGR(5Y)
-- -- -- -- -- -- -26.36% 15.313%
Dividend CAGR(3Y)
-- -- -- -- -- -- 18.21% 14.753%
Dividend CAGR(5Y)
-- -- -- -- -- -- 31.88% 10.757%
FCF 1 Year Growth
-- -- -- -- -- -- -27.64% 20.512%
FCF CAGR(3Y)
-- -- -- -- -- -- 222.85% 29.058%
FCF CAGR(5Y)
-- -- -- -- -- -- -76.14% 7.464%
Currency Unit
USDUSDUSDUSD

FY: Financial Year Annual Report, which is equivalent to the 10-K file disclosed by the listed company to the SEC.

Q: Quarterly report, which is equivalent to the 10-Q file disclosed by the listed company to the SEC, where Q1, Q2, Q3, and Q4 are single quarterly reports with a span of 3 months; Q6 and Q9 are cumulative quarterly reports, and Q6 is 6 months , Q9 is 9 months.

The MOM data from the Quarterly report,MOM=(current period - last period)/last period *100%

Company Overview More
Eli Lilly & Co. engages in the discovery, development, manufacture and sale of pharmaceutical products. The firm's products consist of Diabetes, Oncology, Immunology, Neuroscience, and Other therapies. The Diabetes products include Baqsimi, Basaglar, Humalog, Humulin, Jardiance, Lyumjev, Trajenta, and Trulicity. The Oncology products consist of Alimta, Cyramza, Erbitux, Retevmo, Tyvyt, and Verzenio. The Immunology products include Olumiant and Taltz. The Neuroscience products consist of Cymbalta, Emgality, Reyvow, and Zyprexa. The Other therapies include Bamlanivimab, Cialis, and Forteo. The company was founded by Eli Lilly in May 1876 and is headquartered in Indianapolis, IN.
CEO: Mr. David A. Ricks
Market: NYSE
Listing Date: 04/01/1973
Hot List
TradeSearchNews
SymbolLatest price%Chg

Loading...

Watchlist